## SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500034 STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2013

| PART - I |  |  |  |  | ₹ in lakhs), except share data |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sl. No. | PARTICULARS | Quarter Ended |  |  | Year to date figures | Previous Year Ended |
|  |  | 31/03/2013 | 31/12/2012 | 31/03/2012 | 31/03/2013 | 31-03-12 |
|  |  | Audited | Un-audited | Audited | Audited | Audited |
| 1 | Income from operations |  |  |  |  |  |
|  | (a) Net sales/ income from operations (Net of excise duty) <br> (b) Other operating income | $7,470.36$ | $6,239.48$ | $6,289.42$ | $25,788.46$ | $20,420.78$ |
|  | Total income from operations (net) | 7,470.36 | 6,239.48 | 6,289.42 | 25,788.46 | 20,420.78 |
| 2 | Expenses <br> a) Cost of materials consumed <br> b) Purchases of stock-in-trade <br> c) Changes in inventories of finished goods, work-in-progress and stock-in-trade <br> d) Employee benefits expense <br> e) Depreciation and amortisation expense <br> f) Other expenses - Manufacturing Exps <br> - Selling Exps <br> - Administrative Exps <br> - R \& D Exps <br> - Provision for MTM on Forward contracts <br> Total expenses | $\begin{array}{r} 2,634.47 \\ - \\ 185.25 \\ 554.62 \\ 214.43 \\ 1,147.76 \\ 223.65 \\ 409.34 \\ 982.12 \\ (26.07) \\ 6,325.57 \end{array}$ | $2,364.64$ - $(773.81)$ 768.53 219.01 $1,014.79$ 95.36 264.22 929.72 89.38 $4,971.84$ | $2,487.22$ <br> 418.09 <br> 633.69 <br> 182.78 <br> 791.31 <br> 43.86 <br> 446.39 <br> 821.77 <br> $(854.63)$ <br> $4,970.48$ | $\begin{array}{r} 8,827.40 \\ - \\ (559.63) \\ 2,537.70 \\ 786.72 \\ 3,904.81 \\ 502.80 \\ 1,787.50 \\ 3,469.32 \\ - \\ 21,256.62 \end{array}$ | $\begin{array}{r} 8,145.56 \\ (564.74) \\ 2,283.03 \\ 599.79 \\ 2,667.83 \\ 216.91 \\ 1,704.57 \\ 3,304.91 \\ 348.06 \\ 18,705.92 \end{array}$ |
| 3 4 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) <br> Other Income | $\begin{array}{r} 1,144.79 \\ 54.29 \end{array}$ | $\begin{array}{r} 1,267.64 \\ 36.84 \end{array}$ | $\begin{array}{r} 1,318.94 \\ (148.59) \end{array}$ | $\begin{array}{r} 4,531.84 \\ 104.34 \end{array}$ | $\begin{array}{r} 1,714.86 \\ 190.25 \end{array}$ |
| 5 6 | Profit / (Loss) from ordinary activities before finance costs and exceptional items ( $3 \pm 4$ ) <br> Finance costs | $\begin{array}{r} 1,199.08 \\ 270.74 \end{array}$ | $\begin{array}{r} 1,304.48 \\ 468.53 \end{array}$ | $\begin{array}{r} 1,170.35 \\ 420.86 \end{array}$ | $\begin{aligned} & 4,636.18 \\ & 1,350.94 \end{aligned}$ | $\begin{array}{r} 1,905.11 \\ 990.93 \end{array}$ |
| 7 | Profit / (Loss) from ordinary activities after finance costs but before exceptional items ( $5 \pm 6$ ) <br> Exceptional Items | 928.34 . | $835.95$ | 749.49 | 3,285.24 | 914.18 |
| 9 10 | Profit/Loss from Ordinary Activities before tax (7 $\pm$ 8) <br> Tax Expenses | 928.34 65.30 | $\begin{array}{r} 835.95 \\ 60.27 \end{array}$ | $\begin{array}{r} 749.49 \\ 34.91 \end{array}$ | $\begin{array}{r} \hline 3,285.24 \\ 201.29 \end{array}$ | $\begin{gathered} 914.18 \\ (522.06) \end{gathered}$ |
| $\begin{aligned} & 11 \\ & 12 \end{aligned}$ | Net Profit/ (Loss) from Ordinary Activities after tax (9 $\pm$ 10) <br> Extraordinary Items (net of tax expense ₹ $\qquad$ Lakhs) | $863.04$ | $775.68$ | $714.58$ | $3,083.95$ | $1,436.24$ |
| 13 | Net Profit ( + //Loss(-) for the period (11 $\pm$ 12) | 863.04 | 775.68 | 714.58 | 3,083.95 | 1,436.24 |
| 14 | Share of profit / (loss) of associates* | - | - | - | - | - |
| 15 | Minority interest * | - | - | - | - | - |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates ( $13 \pm 14 \pm 15$ ) * |  |  |  |  |  |
| 17 | Paid-up equity share capital <br> (Face Value of the Share shall be indicated) | $\begin{array}{r} 1,168.29 \\ \text { Re. } 1.00 \end{array}$ | $\begin{array}{r} \hline 1,167.32 \\ \text { Re. } 1.00 \end{array}$ | $\begin{array}{r} 1,167.32 \\ \text { Re. } 1.00 \end{array}$ | $\begin{array}{r} \hline 1,168.29 \\ \text { Re. } 1.00 \end{array}$ | $\begin{array}{r} 1,167.32 \\ \text { Re. } 1.00 \end{array}$ |
| 18 | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | - | - | - | 14,277.69 | 11,584.83 |
| 19.i | Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs. 1/- each) (not annualised): <br> a) Basic <br> b) Diluted | $\begin{aligned} & 0.74 \\ & 0.74 \end{aligned}$ | $\begin{aligned} & 0.66 \\ & 0.66 \end{aligned}$ | $\begin{aligned} & 0.61 \\ & 0.61 \end{aligned}$ | $\begin{aligned} & 2.64 \\ & 2.64 \end{aligned}$ | $\begin{aligned} & 1.23 \\ & 1.23 \end{aligned}$ |
| 19.ii | Earning Per Share (EPS) (after extraordinary items) (of Rs.1/each) (not annualised): <br> a) Basic <br> b) Diluted | $\begin{aligned} & 0.74 \\ & 0.74 \end{aligned}$ | $\begin{aligned} & 0.66 \\ & 0.66 \end{aligned}$ | 0.61 0.61 | 2.64 2.64 | 1.23 1.23 |


| PART - II |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 31/03/2013 | 31/12/2012 | 31/03/2012 | 31/03/2013 | 31-03-12 |
| A | PARTICULARS OF SHAREHOLDING | Audited | Un-audited | Audited | Audited | Audited |
| 1 | Public share holdings <br> - Number of shares <br> - Percentage of Share holding | $\begin{array}{r} 41,993,960 \\ 35.94 \% \end{array}$ | $\begin{array}{r} 42,679,160 \\ 36.56 \% \end{array}$ | $\begin{array}{r} 42,679,160 \\ 36.56 \% \end{array}$ | $\begin{array}{r} 41,993,960 \\ 35.94 \% \end{array}$ | $\begin{array}{r} 42,679,160 \\ 36.56 \% \end{array}$ |
| 2 | Promoters and promoter group Shareholding** <br> a) Pledged / Encumbered <br> - Number of shares <br> - Percentage of Shares (as a \% of the total shareholding of promoter and promoter group) <br> - Percentage of shares (as a \% of the total share capital of the company) <br> b) Non-Encumbered <br> - Number of shares <br> - Percentage of Shares (as a \% of the total shareholding of promoter and promoter group) <br> - Percentage of shares (as a \% of the total share capital of the company) | $\begin{array}{r} \text { NIL } \\ \text { NIL } \\ \text { NIL } \\ 74,834,828 \\ 100.00 \% \\ 64.06 \% \end{array}$ | NIL NIL NIL $74,052,828$ $100.00 \%$ $63.44 \%$ | $\begin{array}{r} \mathrm{NIL} \\ \mathrm{NIL} \\ \mathrm{NIL} \\ 74,052,828 \\ \\ 100.00 \% \\ 63.44 \% \end{array}$ | $\begin{array}{r} \text { NIL } \\ \text { NIL } \\ \text { NIL } \\ 74,834,828 \\ 100.00 \% \\ 64.06 \% \end{array}$ | $\begin{array}{r} \text { NIL } \\ \text { NIL } \\ \text { NIL } \\ 74,052,828 \\ 100.00 \% \\ 63.44 \% \end{array}$ |
|  | Particulars | 3 months ended (31/03/2013) |  |  |  |  |
| B | INVESTOR COMPLAINTS <br> Pending at the beginning of the quarter <br> Received during the quarter <br> Disposed of during the quarter <br> Remaining unresolved at the end of the quarter | $\begin{array}{r} 0 \\ 27 \\ 27 \\ 0 \\ \hline \end{array}$ |  |  |  |  |



Notes: 1) The above audited results were approved and taken on record at the Board of Directors' meeting held on 14th' May '13
2) Previous years figures have been regrouped / reclassified whenever necessary.
3) The figures of the last quarter are the balancing figures between audited figures inrespect of full year and un-audited declared upto 3rd quarter ending.
4) Suven Nishtaa Pharma Pvt Ltd, the $100 \%$ subsiadary, has been merged w.e.f. 1st J an 2012. Hence the current year's figures are not comparable with the previous year figures.
5) The Board has recommended a Dividend of Re. 0.30 per Equity share (i.e. $30 \%$ of face value of Rs. 1/-each) for the year 2012-13, subject to approval of the shareholders in the ensuing Annual General Meeting.

For SUVEN LIFE SCIENCES LTD

